Frank J Vajda
Affiliation: St Vincent's Hospital
- Neuroprotection and neurodegenerative diseaseFrank J E Vajda
Australian Centre for Clinical Neuropharmacology, St Vincent s Hospital, Melbourne, Victoria, 3065, Australia
J Clin Neurosci 9:4-8. 2002..New drugs would also need to be shown to be safe and acceptable, physiologically not detrimental to humans and free from idiosyncratic adverse effects...
- Letter to the neurology editorFrank J E Vajda
J Clin Neurosci 12:210. 2005
- The Australian antiepileptic drug in pregnancy register: aspects of data collection and analysisFrank J E Vajda
Monash University and Medical Centre, 246 Clayton Road, Clayton, Victoria 3168, Australia
J Clin Neurosci 14:936-42. 2007..It is desirable to have available such analyses of pregnancy register data before comparing the findings of different registers...
- Maternal valproate dosage and foetal malformationsF J E Vajda
Raoul Wallenberg Centre, St Vincent s Hospital, Australian Centre for Clinical Neuropharmacology, University of Melbourne, Melbourne, Australia
Acta Neurol Scand 112:137-43. 2005....
- Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancyFrank J Vajda
Department of Medicine, The Australian Centre For Neuropharmacology, Raoul Wallenberg Centre, St Vincent s Hospital, Fitzroy, 3065 Melbourne, Vic, Australia
J Clin Neurosci 11:854-8. 2004..A prospective, observational, community-based cohort study...
- The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 monthsFrank J Vajda
Australian Centre for Neuropharmacology, Raoul Wallenberg Centre, St Vincent s Hospital, Melbourne, Australia
J Clin Neurosci 10:543-9. 2003..It is uncertain how much of this risk is directly caused by the AEDs and whether certain drugs or combinations are associated with a greater risk...
- Dose dependence of fetal malformations associated with valproateFrank J Vajda
From the Department of Medicine and Neuroscience F J V, T J O, J E G, University of Melbourne, Royal Melbourne Hospital, Parkville and University of Queensland C M L, M J E, Royal Brisbane Hospital, Brisbane, Australia
Neurology 81:999-1003. 2013..To study the relationships between maternal valproate dose in pregnancy and the pattern of various fetal malformations...
- Epilepsy and porphyria: new perspectivesCarlo Solinas
Australian Centre for Clinical Neuropharmacology Raoul Wallenberg Centre, Centre for Clinical Neuroscience, St Vincent s Hospital, University of Melbourne, Vic, Australia
J Clin Neurosci 11:356-61. 2004..Application of neuroimaging may detect epileptogenic foci, helping to define the specific risk of seizures for each patient...
- The internal control group in a register of antiepileptic drug use in pregnancyFrank J E Vajda
Department of Medicine, Monash University and Medical Centre, 246 Clayton Road, Clayton, Victoria 3468, Australia
J Clin Neurosci 15:29-35. 2008....
- Seizure control in antiepileptic drug-treated pregnancyFrank J E Vajda
Monash University and Medical Centre, Clayton, Victoria 3168, Australia
Epilepsia 49:172-6. 2008..Once there had been 1 year's freedom from seizures there seemed relatively little further advantage in deferring pregnancy to avoid seizures returning while pregnant...
- The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnanciesFrank J E Vajda
Department of Medicine, Monash University and Medical Centre, Clayton, Victoria, Australia
Aust N Z J Obstet Gynaecol 47:468-74. 2007..Prospective studies are needed to assess the maternal and fetal hazards of antiepileptic drug (AED) therapy in pregnancy...
- Monitoring antiepileptic drug therapy with serum level measurementsFrank J E Vajda
Monash Medical Centre, Monash University, Melbourne, Vic, Australia
Med J Aust 187:581. 2007
- Pharmacotherapy of epilepsy: new armamentarium, new issuesFrank J E Vajda
Department of Medicine, Monash University and Medical Centre, 246 Clayton Road, Clayton 3168, Victoria, and Department of Medicine, St Vincents Hospital, Melbourne, Australia
J Clin Neurosci 14:813-23. 2007..With improvement in diagnostic techniques and new therapeutic modalities it is likely that in the future, pharmacogenomics and an understanding of pharmacoresistance may influence drug selection for individual patients with epilepsy...
- Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm studyRoy G Beran
Strategic Health Evaluators and University of New South Wales, 12 Thomas Street, Suite 5, 6th Floor, Chatswood, NSW 2067, Australia
Epilepsy Res 63:1-9. 2005..To evaluate the efficacy and tolerability of levetiracetam as add-on therapy in patients with refractory partial-onset seizures in a protocol designed to reflect clinical practice...
- The influence of gender on the aggravation of absence seizures by carbamazepine in the low-dose pentylenetetrazol rat modelKaren J McLean
Australian Centre for Clinical Neuropharmacology, Raoul Wallenerg Centre, Melbourne, Vic, Australia
Seizure 13:208-16. 2004..To determine whether carbamazepine (CBZ) aggravates absence seizures in the low-dose pentylenetetrazol (PTZ) rat model in both male and female animals, and investigate for gender differences...